Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis

Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis

Treatment of hepatocellular carcinoma (HCC) is rapidly evolving, with many new therapeutic options; in particular, immunotherapy (IT) is acquiring a major role, even in combination regimens. Despite these promising results, an important limitation is the lack of prognostic and predictive factors tha...

Full description

Bibliographic Details
Main Authors: Ilario Giovanni Rapposelli, Serena De Matteis, Paola Lanuti, Martina Valgiusti, Giulia Bartolini, Paola Ulivi, Giorgia Marisi, Federica Pedica, Valentina Burgio, Giovanni Luca Frassineti, Stefano Cascinu, Andrea Casadei-Gardini
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Cancers
Subjects:
hepatocellular carcinoma
immunotherapy
pattern of response
peripheral blood mononuclear cells
Online Access:https://www.mdpi.com/2072-6694/13/2/213

Internet

https://www.mdpi.com/2072-6694/13/2/213

Similar Items